Industry resources and insights

Sort by year
  • All time
  • 2026
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020 and older
Articles
30.03.2026
From Evidence to Negotiation: Succeeding Under Ita...

From 1 April 2026, AIFA’s updated HTA guidelines will come into effect, making ...

Read more
Articles
30.03.2026
TrumpRx in Focus: Assessing the Implications for ...

Our previous article explored how TrumpRx might influence drug pricing in the US, the potential ...

Read more
Webinar
30.03.2026
Most Favoured Nation (MFN) Policy: Latest Developm...

This on-demand session provides a concise update on recent developments in Most Favoured Nation (MFN...

Read more
Insider Insights
09.03.2026
World EPA 2026: Key Insights, Research Poster &...

World Evidence, Pricing and Access (World EPA) Congress 2026 brought together market access leaders,...

Read more
Poster
02.03.2026
Private versus public access: Exploring how obesit...

Obesity medicines (OMs), including GLP-1 receptor agonists such as semaglutide (Wegovy®) and tirzep...

Read more
Articles
25.02.2026
Orphan Drug Designation: A Head Start, Not a Fre...

Manufacturers looking to optimise access for their orphan drugs need to navigate a complex environme...

Read more
Load more
Browse by topic
Content type
  • All
  • Articles
  • Case Studies
  • Checklist
  • Guide
  • Insider Insights
  • News
  • Poster
  • Publications
  • Webinar
Subscribe
This field is for validation purposes and should be left unchanged.
This field is hidden when viewing the form
Consent

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch